/ 2 items

#INSM↓

Featured/ DSGN/ 03/16/2026 · 12:42 PM

Jefferies Goes All-In on Biotech: 5 Buy-Rated Stocks Poised for Big 2026 Catalysts

Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228).

INSM/ 12/17/2025 · 4:14 PM

Insmed Halts Sinus Treatment, Acquires New Drug Candidate

Insmed discontinues brensocatib for chronic sinus disease after failed trial but adds promising antibody therapy INS1148 to its pipeline for lung and immune conditions.